Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Ovarian Carcinosarcoma and Its Association with Mature Cystic Teratoma and Primary Tubal Carcinoma.

Rewsuwan S, Satabongkoch N, Suprasert P, Khunamornpong S.

Case Rep Pathol. 2016;2016:2605045.

2.

Cytologic studies of the fallopian tube in patients undergoing salpingo-oophorectomy.

Chen H, Klein R, Arnold S, Chambers S, Zheng W.

Cancer Cell Int. 2016 Oct 1;16:78.

3.

Mutant p53 regulates ovarian cancer transformed phenotypes through autocrine matrix deposition.

Iwanicki MP, Chen HY, Iavarone C, Zervantonakis IK, Muranen T, Novak M, Ince TA, Drapkin R, Brugge JS.

JCI Insight. 2016 Jul 7;1(10). pii: e86829.

4.

High-risk HPV is not associated with epithelial ovarian cancer in a Caucasian population.

Ingerslev K, Hogdall E, Skovrider-Ruminski W, Schnack TH, Karlsen MA, Nedergaard L, Hogdall C, Blaakær J.

Infect Agent Cancer. 2016 Jul 14;11:39. doi: 10.1186/s13027-016-0087-4.

5.

Serous carcinoma arising from uterine adenomyosis/adenomyotic cyst of the cervical stump: a report of 3 cases.

Lu B, Chen Q, Zhang X, Cheng L.

Diagn Pathol. 2016 Jun 4;11(1):46. doi: 10.1186/s13000-016-0496-0.

6.

Opportunistic salpingectomy for ovarian cancer prevention.

Hanley GE, McAlpine JN, Kwon JS, Mitchell G.

Gynecol Oncol Res Pract. 2015 Sep 17;2:5. doi: 10.1186/s40661-015-0014-1. Review.

7.

Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms.

Cobb LP, Gaillard S, Wang Y, Shih IeM, Secord AA.

Gynecol Oncol Res Pract. 2015 May 12;2:1. doi: 10.1186/s40661-015-0008-z.

8.

Rationale for Developing a Specimen Bank to Study the Pathogenesis of High-Grade Serous Carcinoma: A Review of the Evidence.

Sherman ME, Drapkin RI, Horowitz NS, Crum CP, Friedman S, Kwon JS, Levine DA, Shih IeM, Shoupe D, Swisher EM, Walker J, Trabert B, Greene MH, Samimi G, Temkin SM, Minasian LM.

Cancer Prev Res (Phila). 2016 Sep;9(9):713-20. doi: 10.1158/1940-6207.CAPR-15-0384. Review.

PMID:
27221539
9.

Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant High-Grade Serous ovarian cancer.

Fransson Å, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N.

J Ovarian Res. 2016 May 14;9(1):27. doi: 10.1186/s13048-016-0239-6.

10.

Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic TP53 mutations in noncancerous tissues.

Krimmel JD, Schmitt MW, Harrell MI, Agnew KJ, Kennedy SR, Emond MJ, Loeb LA, Swisher EM, Risques RA.

Proc Natl Acad Sci U S A. 2016 May 24;113(21):6005-10. doi: 10.1073/pnas.1601311113.

11.

Tubal ligation and incidence of 26 site-specific cancers in the Million Women Study.

Gaitskell K, Coffey K, Green J, Pirie K, Reeves GK, Ahmed AA, Barnes I, Beral V.

Br J Cancer. 2016 Apr 26;114(9):1033-7. doi: 10.1038/bjc.2016.80.

PMID:
27115569
12.

Impact and mechanistic role of oral contraceptive pills on the number and epithelial type of ovarian cortical inclusion cysts; a clinicopathology and immunohistochemical study.

DastranjTabrizi A, MostafaGharabaghi P, SheikhzadehHesari F, Sadeghi L, Zamanvandi S, Sarbakhsh P, Ghojazadeh M.

Diagn Pathol. 2016 Mar 22;11:30. doi: 10.1186/s13000-016-0482-6.

13.

It's Totally Tubular....Riding The New Wave of Ovarian Cancer Research.

Perets R, Drapkin R.

Cancer Res. 2016 Jan 1;76(1):10-7. doi: 10.1158/0008-5472.CAN-15-1382. Review.

PMID:
26669862
14.

Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer.

Meinhold-Heerlein I, Fotopoulou C, Harter P, Kurzeder C, Mustea A, Wimberger P, Hauptmann S, Sehouli J; Kommission Ovar of the AGO..

Geburtshilfe Frauenheilkd. 2015 Oct;75(10):1021-1027.

15.

Early salpingectomy (TUbectomy) with delayed oophorectomy to improve quality of life as alternative for risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers (TUBA study): a prospective non-randomised multicentre study.

Harmsen MG, Arts-de Jong M, Hoogerbrugge N, Maas AH, Prins JB, Bulten J, Teerenstra S, Adang EM, Piek JM, van Doorn HC, van Beurden M, Mourits MJ, Zweemer RP, Gaarenstroom KN, Slangen BF, Vos MC, van Lonkhuijzen LR, Massuger LF, Hermens RP, de Hullu JA.

BMC Cancer. 2015 Aug 19;15:593. doi: 10.1186/s12885-015-1597-y.

16.

Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.

Vang R, Levine DA, Soslow RA, Zaloudek C, Shih IeM, Kurman RJ.

Int J Gynecol Pathol. 2016 Jan;35(1):48-55. doi: 10.1097/PGP.0000000000000207.

17.

PAX8 expression in ovarian surface epithelial cells.

Adler E, Mhawech-Fauceglia P, Gayther SA, Lawrenson K.

Hum Pathol. 2015 Jul;46(7):948-56. doi: 10.1016/j.humpath.2015.03.017.

18.

Should Fallopian Tubes Be Removed During Hysterectomy Procedures? - A Statement by AGO Ovar.

Pölcher M, Hauptmann S, Fotopoulou C, Schmalfeldt B, Meinhold-Heerlein I, Mustea A, Runnebaum I, Sehouli J; Kommission Ovar of the Gynecologic Oncology Study Group (AGO)..

Geburtshilfe Frauenheilkd. 2015 Apr;75(4):339-341. No abstract available.

19.

Ovarian cancer risk reduction through opportunistic salpingectomy.

Kwon JS.

J Gynecol Oncol. 2015 Apr;26(2):83-6. doi: 10.3802/jgo.2015.26.2.83. No abstract available.

20.

Pathobiology of ovarian carcinomas.

Devouassoux-Shisheboran M, Genestie C.

Chin J Cancer. 2015 Jan;34(1):50-5. doi: 10.5732/cjc.014.10273. Review.

Items per page

Supplemental Content

Support Center